Δ-β2M as a dynamic biomarker for predicting ICU admission after CAR T-cell therapy
Alexander C. Angleitner, Markus Maulhardt, Kristian Thomson, Judith Büntzel, Gerald Wulf · 2026
Read Δ-β2M as a dynamic biomarker for predicting ICU admission after CAR T-cell therapy by Alexander C. Angleitner, Markus Maulhardt, Kristian Thomson, Judith Büntzel, Gerald Wulf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13212766.txt.
Description
Alexander C. Angleitner and co-authors test in 2026 whether a simple blood marker can flag which patients will need intensive care after CAR T-cell therapy. The treatment, which reprogrammes a patient's own immune cells against cancer, can trigger dangerous side effects.
The marker tracks change in a protein called beta-2 microglobulin between infusion day and day three. In one main cohort and two later validation groups, the change separated patients who later needed intensive care with fair to good accuracy. It did not predict a separate brain-related side effect. Standard markers such as C-reactive protein performed inconsistently. The authors propose wider testing of early marker changes in risk models.
Catalog record
| CREATOR | Alexander C. Angleitner, Markus Maulhardt, Kristian Thomson, Judith Büntzel, Gerald Wulf |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |